Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

Market Cap	5.85B +58.4%
Revenue (ttm)	871.31M +3.0%
Net Income	57.12M -50.2%
EPS	0.36 -50.3%
Shares Out	159.01M
PE Ratio	101.09
Forward PE	n/a
Dividend	0.60 (1.63%)
Ex-Dividend Date	Jun 9, 2025

Volume	2,360,000
Average Volume	2,354,471
Open	36.33
Previous Close	36.76
Day's Range	36.30 - 37.75
52-Week Range	22.91 - 67.98
Beta	0.52
RSI	43.28
Earnings Date	Apr 23, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 668
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603590

Financial Performance

In 2024, SHA:603590's revenue was 825.40 million, a decrease of -10.28% compared to the previous year's 920.01 million. Earnings were 42.22 million, a decrease of -71.94%.